Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 5, 2012, Pages 577-583

  Yasuno, Shinji ^a   Fujimoto, Akira ^a   Nakagawa, Yasuaki ^a   Kuwahara, Koichiro ^a   Ueshima, Kenji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

amlodipine; candesartan; fixed dose combination therapy; hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS CANDESARTAN HEXETIL; AMLODIPINE PLUS TELMISARTAN; AMLODIPINE PLUS VALSARTAN; AZELNIDIPINE; CANDESARTAN; OLMESARTAN;

BLOOD PRESSURE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIZZINESS; FOLLOW UP; FRACTURE; HUMAN; HYPERTENSION; JAPAN; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; PERIPHERAL EDEMA; PNEUMONIA; REVIEW; THORAX PAIN;

ADMINISTRATION, ORAL; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DRUG COMBINATIONS; HUMANS; HYPERTENSION; JAPAN; TETRAZOLES;

EID: 84861872923     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.34     Document Type: Review

References (42)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 360(9343), 1347-1360 (2002).
2. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: Therapeutic potential. Pharmacol. Ther. 111(1), 81-98 (2006).
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 365(9455), 217-223 (2005).
4. Ogihara T, Kikuchi K, Matsuoka H et al.; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens. Res. 32(1), 3-107 (2009).
5. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51(6), 1403-1419 (2008).
6. Ohkubo T, Obara T, Funahashi J et al.; J-HOME Study Group. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens. Res. 27(10), 755-763 (2004).
7. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 303(20), 2043-2050 (2010).
8. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-Analysis. Lancet 358(9290), 1305-1315 (2001).
9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913 (2002).
10. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 370(9587), 591-603 (2007).
11. Sarafidis PA, Bakris GL. Resistant hypertension: An overview of evaluation and treatment. J. Am. Coll. Cardiol. 52(22), 1749-1757 (2008).
12. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124(9), 1046-1058 (2011).
13. Gradman AH, Basile JN, Carter BL et al. Combination therapy in hypertension. J. Am. Soc. Hypertens. 4(2), 90-98 (2010).
14. Black HR. Triple fixed-dose combination therapy: Back to the past. Hypertension 54(1), 19-22 (2009).
15. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: Meta-Analysis on 11,000 participants from 42 trials. Am. J. Med. 122(3), 290-300 (2009).
16. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
17. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 62(3), 443-462 (2002).
18. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: Adherence and systolic blood pressure control. Clin. Ther. 29(5), 972-984 (2007).
19. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-Analysis. Hypertension 55(2), 399-407 (2010).
20. Ogihara T, Nakao K, Fukui T et al.; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51(2), 393-398 (2008).
21. Schrader J, Lüders S, Kulschewski A et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 34(7), 1699-1703 (2003).
22. Kloner RA, Weinberger M, Pool JL et al.; Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am. J. Cardiol. 87(6), 727-731 (2001).
23. Kasanuki H, Hagiwara N, Hosoda S et al.; HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-Angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur. Heart J. 30(10), 1203-1212 (2009).
24. Lithell H, Hansson L, Skoog I et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J. Hypertens. 21(5), 875-886 (2003).
25. Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008).
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288, 2981-2997 (2002).
27. Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
28. Berl T, Hunsicker LG, Lewis JB et al.; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with Type 2 diabetes and overt nephropathy. Ann. Intern. Med. 138(7), 542-549 (2003).
29. Julius S, Kjeldsen SE, Weber M et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363(9426), 2022-2031 (2004).
30. Narumi H, Takano H, Shindo S et al.; Valsartan Amlodipine Randomized Trial Investigators. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: The Valsartan Amlodipine Randomized Trial. Hypertens. Res. 34(1), 62-69 (2011).
31. Ogihara T, Ueshima K, Nakao K et al.; CASE-J Ex Study Group. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: The Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertens. Res. 34(12), 1295-1301 (2011).
32. Yamaguchi J, Hagiwara N, Ogawa H et al.; HIJ-CREATE Investigators. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study). Am. J. Cardiol. 106(6), 819-824 (2010).
33. Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin. Pharmacokinet. 41(1), 7-17 (2002).
34. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br. J. Clin. Pharmacol. 22(1), 21-25 (1986).
35. Beresford AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA. Metabolism and kinetics of amlodipine in man. Xenobiotica 18(2), 245-254 (1988).
36. Opie LH. Pharmacological differences between calcium antagonists. Eur. Heart J. 18 (Suppl. A), A71-A79 (1997).
37. Messerli FH. Evolution of calcium antagonists: Past, present, and future. Clin. Cardiol. 26(2 Suppl. 2), II12-II16 (2003).
38. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther. 29(4), 563-580 (2007).
39. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
40. Bakris GL, Sarafidis PA, Weir MR et al.; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 375(9721), 1173-1181 (2010).
41. Jamerson KA, Devereux R, Bakris GL et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 57(2), 174-179 (2011).
42. Ogihara T, Saruta T, Rakugi H et al.; COLM study investigators. Rationale, study design and implementation of the COLM study: The combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens. Res. 32(2), 163-167 (2009).